Skip to main content

Clinical management and dose modifications with an immunomodulatory treatment in relapsed/refractory multiple myeloma

April 16, 2021

Brought to you by Bristol Myers Squibb

This program will share information about a treatment option for relapsed/refractory multiple myeloma including the impact of multiple myeloma on patients, dose modifications for consideration due to adverse events, and approaches to keep patients on therapy. 

Blog category